Neuropsychiatric and neurodegenerative disorders are complex and involve multiple neuronal circuits. It is therefore not surprising that many of the most efficacious drugs, such as clozapine for schizophrenia, were discovered by serendipity (basically by observing how an animal’s behavior was altered in response to the drug). PsychoGenics has pioneered the translation of rodent behavioral responses into meaningful clinical candidates through its robust, in vivo, high content, high throughput screening platforms; these platforms form the core of drug discovery partnerships with major pharmaceutical companies.
There are currently three proprietary platforms, SmartCube®, NeuroCube™ and PhenoCube™. Using these platforms PsychoGenics can screen tens of thousands of compounds for CNS activity and identify those with a behavioral profile that reverses a disease model phenotype or that are similar to drugs that treat a specific neuropsychiatric disorder. The company’s technologies are being applied to discover treatments for psychiatric, cognitive and neuromotor/degenerative disorders, and pain.
PsychoGenics partners include Eli Lilly, Roche and Sunovion (formerly Sepracor).